Christos Sachpekidis

List of Publications by Year
in descending order

78 papers	1,961 citations	257450 24 h-index	276875 41 g-index
80 all docs	80 docs citations	80 times ranked	2332 citing authors

#	Article	IF	Citations
1	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 376-383.	6.4	160
2	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 386-396.	6.4	130
3	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	6.4	124
4	Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 21-39.	6.4	96
5	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1289-1296.	6.4	90
6	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e473-e479.	1.3	86
7	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clinical and Translational Imaging, 2017, 5, 183-197.	2.1	59
8	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1343-1353.	6.4	55
9	NF1 loss induces senescence during human melanocyte differentiation in an <scp>iPSC</scp>â€based model. Pigment Cell and Melanoma Research, 2015, 28, 407-416.	3.3	52
10	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. Computational and Structural Biotechnology Journal, 2019, 17, 177-185.	4.1	51
11	Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 614-623.	6.4	47
12	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	4.2	45
13	Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 479-92.	1.0	45
14	Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 469-78.	1.0	44
15	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	1.2	43
16	18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, e300-e307.	1.3	41
17	Clinical significance of signs of autoimmune colitis in ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy, 2019, 11, 667-676.	2.0	41
18	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	6.4	37

#	Article	IF	Citations
19	68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 904-912.	6.4	34
20	Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. Annals of Nuclear Medicine, 2021, 35, 485-492.	2.2	34
21	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Research, 2016, 6, 61.	2.5	29
22	Radioimmunotherapy in Non-Hodgkinâ€™s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar. Pharmaceuticals, 2019, 12, 141.	3.8	29
23	The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 642-651.	6.4	29
24	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancerâ€”a modified protocol compared with the common protocol. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 624-631.	6.4	26
25	18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 592-602.	6.4	26
26	Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. Journal of Nuclear Medicine, 2021, 62, 1252-1257.	5.0	26
27	Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 160-167.	6.4	25
28	PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin Î±vÎ²3 Receptors. Molecules, 2021, 26, 1792.	3.8	25
29	Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 127-42.	1.0	24
30	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics, 2018, 8, 76.	2.6	23
31	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	4.2	22
32	Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2289-2297.	6.4	19
33	The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. European Radiology, 2021, 31, 8030-8039.	4.5	19
34	Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules, 2020, 25, 134.	3.8	18
35	Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. EJNMMI Research, 2018, 8, 28.	2.5	17
36	Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data. Medicina (Lithuania), 2019, 55, 149.	2.0	17

#	Article	IF	Citations
37	Imaging and Imaging-Based Management of Pediatric Thyroid Nodules. Journal of Clinical Medicine, 2020, 9, 384.	2.4	17
38	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	6.4	17
39	PSMA-negative prostate cancer and the continued value of choline-PET/CT. Nuklearmedizin - NuclearMedicine, 2020, 59, 33-34.	0.7	15
40	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Research, 2021, 11, 89.	2.5	15
41	Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. Cancers, 2018, 10, 451.	3.7	12
42	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). Annals of Surgical Oncology, 2019, 26, 1332-1339.	1.5	12
43	Quantitative dynamic ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica, 2019, 104, e420-e423.	3.5	12
44	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers, 2021, 13, 1019.	3.7	12
45	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research, 2021, 11, 100.	2.5	12
46	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. Cancers, 2019, 11, 790.	3.7	11
47	Incidental SARS-CoV-2-related findings in asymptomatic patients in [18F]-FDG-PET/CTâ€"potential insights. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2068-2069.	6.4	11
48	18F-FDG PET/CT of Papillary Carcinoma in a Lateral Thyroglossal Duct Cyst. Clinical Nuclear Medicine, 2017, 42, e371-e374.	1.3	10
49	Parametric Imaging With Dynamic PET for Oncological Applications: Protocols, Interpretation, Current Applications and Limitations for Clinical Use. Seminars in Nuclear Medicine, 2022, 52, 312-329.	4.6	10
50	STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. Cancers, 2020, 12, 119.	3.7	9
51	Positron Emission Tomography in Merkel Cell Carcinoma. Cancers, 2020, 12, 2897.	3.7	9
52	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 351-359.	1.0	9
53	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	3.7	8
54	Equilibrium radionuclide angiography: Intra- and inter-observer repeatability and reproducibility in the assessment of cardiac systolic and diastolic function. Journal of Nuclear Cardiology, 2021, 28, 1304-1314.	2.1	7

#	Article	IF	Citations
55	Bispecific radioligands targeting prostateâ€specific membrane antigen and gastrinâ€releasing peptide receptors on the surface of prostate cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 510-522.	1.0	7
56	Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 148-156.	1.0	7
57	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. Cancers, 2020, 12, 1335.	3.7	6
58	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clinical Nuclear Medicine, 2016, 41, 156-158.	1.3	5
59	99mTc-MAG3 Diuretic Renography: Intra- and Inter-Observer Repeatability in the Assessment of Renal Function. Diagnostics, 2020, 10, 709.	2.6	5
60	Radiosynoviorthesis after Surgery in the Treatment of Patients with Ankle Pigmented Villonodular Synovitis: A Case Series. Journal of Clinical Medicine, 2020, 9, 597.	2.4	5
61	Dynamic18F-fluorodeoxyglucose positron emission tomography/CT in hibernoma: Enhanced tracer uptake mimicking liposarcoma. World Journal of Radiology, 2013, 5, 498.	1.1	5
62	Multimodal Imaging With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging to Detect Extracapsular Extension in Head and Neck Cancer. Laryngoscope, 2021, 131, E163-E169.	2.0	4
63	Detection of a primary tumor in the area of the renal artery with 18F-FDG PET/CT in a patient with metastatic undifferentiated sarcoma and a history of mid-aortic syndrome. Medicine (United States), 2016, 95, e4622.	1.0	3
64	PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges. Immunotherapy, 2019, 11, 1267-1271.	2.0	3
65	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. Cancers, 2020, 12, 1008.	3.7	3
66	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
67	Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD. In Vivo, 2018, 32, 1457-1462.	1.3	2
68	Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. Diagnostics, 2021, 11, 649.	2.6	2
69	Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Diagnostics, 2017, 7, 61.	2.6	1
70	68Gaâ€“Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis. Clinical Nuclear Medicine, 2019, 44, 838-839.	1.3	1
71	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hellenic Journal of Nuclear Medicine, 2017, 20, 251-253.	0.3	1
72	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. Cancers, 2021, 13, 5170.	3.7	1

#	Article	IF	Citations
73	Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. Blood, 2018, 132, 3180-3180.	1.4	1
74	Radiosynovectomy is a safe and an efficient alternative in the treatment of chronic, recurrent knee hemarthrosis. World Journal of Nuclear Medicine, 2020, 19, 165.	0.5	0
75	Atypical metastatic pattern of prostate cancer detected with 68Ga-PSMA PET/CT. Nuklearmedizin - NuclearMedicine, 2020, 59, 85-86.	0.7	0
76	Emotional impairment in a patient with amyotrophic lateral sclerosis: a (99m)Tc-HMPAO SPET brain study. Hellenic Journal of Nuclear Medicine, 2012, 15, 59-62.	0.3	0
77	F-FDG PET/CT in treatment response evaluation of Burkitt lymphoma: complete remission of a peritoneal super scan. Hellenic Journal of Nuclear Medicine, 2020, 23, 76-78.	0.3	0
78	Editorial: Molecular Imaging in Multiple Myeloma: An Update and Future Perspectives. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	0